Details for Patent: 9,161,926

Which drugs does patent 9,161,926 protect, and when does it expire?

Patent 9,161,926 protects ACZONE and is included in one NDA.

This patent has twenty-three patent family members in fifteen countries.

Summary for Patent: 9,161,926

Title:	Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Abstract:	Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
Inventor(s):	Warner; Kevin S. (Anaheim, CA), Parashar; Ajay P. (San Diego, CA), Swaminathan; Vijaya (San Francisco, CA), Bhatt; Varsha (San Francisco, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/082,955
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,161,926
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,161,926

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almirall	ACZONE	dapsone	GEL;TOPICAL	207154-001	Feb 24, 2016	AB	RX	Yes	Yes			Y

International Family Members for US Patent 9,161,926

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013348247
Australia	2018214139
Brazil	112015011673
Canada	2890224
China	105246457